Læknablaðið - 15.06.2006, Blaðsíða 16

FRÆÐIGREINAR / H ELICOBACTER
17. Mclntire JJ, Umetsu SE, Macaubas C, Hoyte EG, Cinnioglu
C, Cavalli-Sforza LL, et al. Immunology: hepatitis A virus link
to atopic disease. Nature 2003; 425: 576.
18. Worldwide variation in prevalence of symptoms of asthma,
allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The
International Study of Asthma and Allergies in Childhood
(ISAAC) Steering Committee. Lancet 1998; 351:1225-32.
19. Hopkin JM. Mechanisms of enhanced prevalence of asthma
and atopy in developed countries. Curr Opin Immunol 1997;
9: 788-92.
20. Esch T, Stefano G. Proinflammation: a common denominator
or initiator of different pathophysiological disease processes.
Med Sci Monit 2002; 8: HYl-9.
21. Pepys MB, Hirschfield GM. C-reactive protein: a critical
update. J Clin Invest 2003; 111:1805-12.
22. Birgisdóttir A, Ásbjörnsdóttir H, Cook E, Gíslason D, Jansson
C, Ólafsson í, et al. Seroprevalence of Toxoplasma gondii
in Sweden, Estonia and Iceland. Scand J Infect Dis 2006: In
press.
23. Olafsdottir IS, Gislason T, Thjodleifsson B, Olafsson I,
Gislason D, Jogi R, et al. C reactive protein levels are
increased in non-allergic but not allergic asthma: a multicentre
epidemiological study. Thorax 2005; 60:451-4.
24. Gislason T, Olafsdottir IS, Thjodleifsson B, Olafsson í.
Gíslason D, Jögi R, Janson C. Highly sensitivity C-reactive
protein (Hs-CRP) is associated with COPD and a faster
decline in FEVl a multicenter epidemioæogical study. Eur
Resp J 2005; 26(Supplement 49. P438): 51s.
25. Burney PG, Luczynska C, Chinn S, Jarvis D. The European
Community Respiratory Health Survey. Eur Respir J 1994; 7:
954-60.
26. The European Community Respiratory Health Survey II. Eur
Respir J 2002; 20:1071-9.
27. Davíð Gíslason Unnur Steina Björnsdóttir, Þorsteinn Blöndal,
Þórarinn Gíslason. Evrópurannsóknin Lungu og heilsa
(ECRHS): Hverjar eru helstu niðurstöður fram að þessu í ljósi
sérstöðu íslands? Læknablaðið 2002; 88: 891-908.
28. Balsari A, Poli G, Molina V, Dovis M, Petruzzelli E, Boniolo
A, et al. ELISA for toxoplasma antibody detection: a
comparison with other serodiagnostic tests. J Clin Pathol 1980;
33: 640-3.
29. Laheij RJ. Straatman H, Jansen JB, Verbeek AL. Evaluation
of commercially available Helicobacter pylori serology kits: a
review. J Clin Microbiol 1998; 36: 2803-9.
30. Wiedmann M, Boehm S, Schumacher W, Swysen C, Zauke
M. Evaluation of three commercial assays for the detection of
hepatitis a virus. Eur J Clin Microbiol Infect Dis 2003; 22:129-
30.
31. Liberatos P, Link BG, Kelsey JL. The measurement of social
class in epidemiology. Epidemiol Rev 1988; 10: 87-121.
32. Standardization of Spirometry, 1994 Update. American Thor-
acic Society. Am J Respir Crit Care Med 1995; 152:1107-36.
33. Jarvis D, Luczynska C, Chinn S, Potts J, Sunyer J, Janson C,
et al. Change in prevalence of IgE sensitization and mean total
IgE with age and cohort. J Allergy Clin Immunol 2005; 116:
675-82.
34. United Nations. Human development indicators. Human
development report. hdr.undp.org 2005.
35. Kato S, Furuyama N, Ozawa K, Ohnuma K, Iinuma K.
Long-term follow-up study of serum immunoglobulin G
and immunoglobulin A antibodies after Helicobacter pylori
eradication. Pediatrics 1999; 104: e22.
36. Xia HH, Talley NJ. Natural acquisition and spontaneous
elimination of Helicobacter pylori infection: clinical
implications. Am J Gastroenterol 1997; 92:1780-7.
37. Davis JP. Experience with hepatitis A and B vaccines. Am J
Med 2005; 118 Suppl 10A: 7S-15S.
38. Feldman HA. A Nationwide Serum Survey Of United States
Military Recruits, 1962. Vi. Toxoplasma Antibodies. Am J
Epidemiol 1965; 681:385-91.
39. Pálsson PA. Ársskýrsla Tilraunastöðvar Háskólans í
Meinafræði. Keldum. 1965.
40. Woodruff AW, de Savigny DH, Hendy-Ibbs PM. Toxocaral
and toxoplasmal antibodies in cat breeders and in Icelanders
exposed to cats but not to dogs. BMJ (Clin Res Ed) 1982; 284:
309-10.
41. Jónsdóttir KE, Árnadóttir T. Mælingar á mótefnum gegn
bogfrymlum í nokkrum hópum íslendinga. Læknablaðið 1988;
74: 279-84.
42. Woodward M, Morrison C, McCoII K. An investigation into
factors associated with Helicobacter pylori infection. J Clin
Epidemiol 2000; 53:175-81.
43. Ferguson DA, Jr., Li C, Patel NR, Mayberry WR, Chi DS,
Thomas E. Isolation of Helicobacter pylori from saliva. J Clin
Microbiol 1993;31:2802-4.
44. Li C, Ha T, Ferguson DA, Jr., Chi DS, Zhao R, Patel NR, et
al. A newly developed PCR assay of H. pylori in gastric biopsy,
saliva, and feces. Evidence of high prevalence of H. pylori in
saliva supports oral transmission. Dig Dis Sci 1996; 41:2142-9.
45. Borgarfræðasetur Háskóla íslands og Reykjavíkurborgar.
Húsnæði og búseta í 100 ár. http://www.borg.hi.is.
46. Briem H. Declining prevalence of antibodies to hepatitis A
virus infection in Iceland. Scand J Infect Dis 1991; 23:135-8.
47. Briem H, Weiland O, Fridriksson I, Berg R. Prevalence of
antibody to hepatitis A in Iceland in relation to age, sex, and
number of notified cases of hepatitis. Am J Epidemiol 1982;
116:451-5.
48. Kosunen TU, Aromaa A, Knekt P, Salomaa A, Rautelin H,
Lohi P, et al. Helicobacter antibodies in 1973 and 1994 in the
adult population of Vammala, Finland. Epidemiol Infect 1997;
119: 29-34.
49. Ma JL, You WC, Gail MH, Zhang L, Blot WJ, Chang YS, et
al. Helicobacter pylori infection and mode of transmission in
a population at high risk of stomach cancer. Int J Epidemiol
1998; 27: 570-3.
50. Kikuchi S, Ohgihara A, Hasegawa A, Miki K, Kaneko E,
Mizukoshi H. Seroconversion and seroreversion of Heli-
cobacter pylori antibodies over a 9-year period and related
factors in Japanese adults. Helicobacter 2004; 9: 335-41.
444 Læknablaðid 2006/92